Skip to main content
  • English
  • Français
  • Español
  • Russian
  • Portuguese

Breadcrumb

  1. Home
  2. Gastroenterology
  3. Fecal transplant: a solution for ici-induced colitis?
  • Our publications
    • News
    • Microbiota Mag
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • Partnerships
    • Press room
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
    • Xpeer App
  • Useful documents
    • Infographic
    About the Institute

    Join the microbiota community

    • Facebook
    • Twitter
    • YouTube

Lay public section

Find here your dedicated section
Gastroenterology
Gynecology
Pediatrics
Dermatology

Breadcrumb

  1. Home
  2. Gastroenterology
  3. Fecal transplant: a solution for ici-induced colitis?
Gastroenterology

Fecal transplant: a solution for ici-induced colitis?

Colitis
Oncology Gastroenterology

A preliminary trial with two patients showed that an allogeneic fecal microbiota transplant could help resorb refractory immune checkpoint inhibitor-associated colitis. This avenue remains to be explored as the field of immuno-oncology is blossoming.

Gastroenterology
Gynecology
Pediatrics
Dermatology
  • Our publications
    • News
    • Microbiota Mag
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • Partnerships
    • Press room
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
    • Xpeer App
  • Useful documents
    • Infographic
    About the Institute

    Join the microbiota community

    • Facebook
    • Twitter
    • YouTube

Lay public section

Find here your dedicated section

Sources

This article is based on scientific information

Sharing is caring

Your colleagues might be interested in this topic. Why not share it?

  • Facebook
  • Twitter
  • Mail

About this article

Created 05 February 2019
Updated 06 October 2021

 

The latest therapeutic advances in oncology owe much to immune checkpoint inhibitors (ICI), monoclonal antibodies currently targeting (sidenote: CTLA-4 Cytotoxic T-lymphocyte-associated antigen 4 ) , (sidenote: PD-1 programmed cell death protein 1 ) and (sidenote: PD-L1 Programmed cell death ligand 1 ) . They are much less toxic than chemotherapy, but the first marketed treatments are still associated with immune-mediated adverse reactions, especially refractory colitis. The optimal treatment of these types of disorders has yet to be found. An American team studied the potential benefits of fecal microbiota transplant (FMT). Objective: fight against ICI-induced dysbiosis and promote bacterial mechanisms combating local inflammatory processes.

Promising initial results

The analysis of the bacterial populations before the fecal transplant in the two patients revealed the absence of protective bacteria (from the Bacteroidia and Verrucomicrobiae classes). The first patient was a 50-year old woman treated for chemotherapy-resistant metastatic transitional cell carcinoma and hospitalized for ICI-associated ulcerative colitis. Since colitis symptoms were resistant to standard treatments, she was transplanted, via colonoscopy, a unique stool dose from a healthy donor. Result: progressive and fast disappearance (36 days) of colic symptoms, confirmed by endoscopy. The second patient was a 78-year old man treated with ICI for chemotherapy- and hormonotherapy-resistant prostate cancer. After the onset of immunotherapy-associated colitis that was resistant to all standard treatments, he received two stool doses (separated by a 67-day interval) from the same healthy donor. Clinical symptoms were partially reduced by the first transplant and eliminated by the second, as demonstrated by endoscopy.

Post-transplant evolution

The analysis of fecal samples collected throughout the study showed that gut microbiota populations changed following the transplant. Although diversity remained stable, bacterial abundance temporary increased in both patients and the recipient’s microbiota became more similar to that of the donor in the days following the transplant. Immediately after the FMT, recipients were once again colonized by bacteria from the Bifidobacterium and Blautia genera, known for overriding the toxicity of ICI in a murine model and associated with the decrease of gastrointestinal inflammation. These preliminary results still need to be confirmed; they could be a possible response to therapeutic needs that will keep increasing as the use of ICI becomes more common.

 

Sources

Y. Wang, D. Wiesnoski, B. Helmink, et al. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nature medicine, 2018 Dec;24(12):1804-1808.

Tags
Fecal transplant ICI Checkpoint inhibitor Cancer Immuno-oncology Oncology FMT

en_view en_sources

    Created 05 February 2019
    Updated 06 October 2021

    About this article

    To know more about this topic.

    Main topic

    Colitis

    Medical practice

    Oncology Gastroenterology

    Content type

    News
    Gastroenterology

    The blue poop challenge: a reliable method to evaluate gut transit?

    By Pr. Gianluca Ianiro Gastroenterology Department, Fondazione Policlinico Universitario Agostino Gemelli- ...

    Find out more

    New perspectives in autism: the role of microbiota in social communication

    Overview By Dr. Vincent Trebossen Child and Adolescent P...

    Find out more

    Gut microbiota #15

    By Pr. Markku Voutilainen Turku University Faculty of Medicine; Turku University Hospital, Department of Ga...

    Find out more

    Microbiome topics at gastro 2021

    Congress Review By Pr. Eamonn M M Quigley Lynda K and David M Underwood Center for Digestive Disorders, Di...

    Find out more

    Commensal clostridiales strains mediate effective anti-cancer immune response against solid tumours

    Commented articles - Adults' section By Pr. Harry Sokol ...

    Find out more

    Microbiota in covid-19 pandemic

    Overview By Pr. Conceição Calhau NOVA Medical School, New University of Lisbon, Portugal By Pr. Pedro Povo...

    Find out more

    Association between fungal dysbiosis and environment

    The fungal portion of the gut microbiota (or mycobiota) has been much less studied than the bacterial porti...

    Find out more

    From diarrhea to chronic diseases: the well-documented consequences of antibiotic-related gut microbiota dysbiosis

    Antibiotic treatment may sometimes take place without any...

    Find out more

    Continue reading

    News
    26.04.2022

    Severe obesity: the vicious circle of biotin metabolism

    Read the article
    22.04.2022

    SCFAs: new intestinal markers of Parkinson’s disease?

    Read the article
    15.04.2022

    Multiple sclerosis and microbiota: does meat consumption play a role?

    Read the article
    08.04.2022

    Inflammatory Bowel Disease (IBD): do microplastics condition severity?

    Read the article
    04.04.2022

    The microbiota, a significant factor in smoking cessation

    Read the article
    30.04.2019

    The lingual microbiota, biomarker of pancreatic cancer?

    Read the article
    15.06.2021

    Autism: link between severity of the disorder and changes in the gut microbiota?

    Read the article
    Actu PRO : A chaque tumeur son microbiote
    20.11.2020

    Each tumor has its own microbiota

    Read the article
    What's worth reading about microbiota
    Follow us on Twitter
    Read our thematic folder
    The Janus face of Antibiotics: Life Savers & Microbiota Disrupters
    NL13_cover
    Check out latest newsletter
    IBS, Microbiota & Covid-19
    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographic
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • YouTube

    Lay public section

    Find here your dedicated section
    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology
    • English
    • Français
    • Español
    • Russian
    • Portuguese

    Browse the site

    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographic
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • YouTube

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology

    Join the microbiota community

    • Facebook
    • Twitter
    • YouTube

    Lay public section

    Find here your dedicated section

    en_redirection

    en_you_are_about_to_leave

    • en_be_redirected
    • en_stay_on_biocodex

    Stay with us !

    Join the Microbiota Community of HCPs and researchers and receive once a month the “Microbiota Digest” to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    Explore

    04.05.2022

    Miscarriage: Is vaginal dysbiosis a suspect?

    Read the article
    26.04.2022

    Severe obesity: the vicious circle of biotin metabolism

    Read the article
    22.04.2022

    SCFAs: new intestinal markers of Parkinson’s disease?

    Read the article

    Stay updated

    Join the Microbiota Community of HCPs and researchers and receive once a month the “Microbiota Digest” to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographic
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • YouTube

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology

    Lay public section

    Find here your dedicated section

    Join the microbiota community

    • Facebook
    • Twitter
    • YouTube

    © 2022 Biocodex. All rights reserved.

    • Cookies Policy
    • Data protection policy
    • GTU
    • Sitemap
    • Cookies settings
    Biocodex logo